Clinical Trial Update: ETA and AT1 Antagonism in ANCA-vasculitis (SPARVASC) [Phase 2]

View source ↗

Summary

This update describes a Phase 2 clinical trial (SPARVASC) examining ETA receptor antagonism and AT1 receptor antagonism in ANCA-associated vasculitis; the study…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anca-associated Vasculitis
• Cardiovascular Diseases
• Kidney Diseases

Snippet

Sponsor: University of Edinburgh | Conditions: ANCA Associated Vasculitis, Cardiovascular Diseases | Phase 2 | Status: ACTIVE_NOT_RECRUITING